Drug Costs bitter pill to insurers
- Specialty pharmacies provide pipeline for low-volume, high-cost biotech drugs. Edlin, Mari // Managed Healthcare Executive;Jun2003, Vol. 13 Issue 6, p36
Discusses issues concerning the inclusion of specialty pharmacies in pharmacy benefit plans. Cost-effectiveness of specialty pharmacies compared to biotech drugs for pharmacy benefit managers; Issue on whether biotech injectables will be covered under the pharmacy or under the medical benefit.
- States Grapple With Making Prescription Drugs Accessible. Connolly, Jim // National Underwriter / Life & Health Financial Services;8/20/2001, Vol. 105 Issue 34, p41
Addresses how states make prescription drugs accessible to people with limited means in the United States. Implementation of a pharmaceutical services insurance program in Maryland; Participation of health insurance companies in the program.
- PBMs: A mighty few. // Family Practice Management;Jul/Aug1998, Vol. 5 Issue 7, p80
Presents statistical information on the service of drug benefits to the United States population by pharmacy benefit management companies (PBMs), as reported in July 1998. Percentage of the market controlled by PBMs; Identification of the PBMs.
- Tiered Pharmacy Benefit Plans on the Rise. Wechsler, Jill // Pharmaceutical Executive;Oct2002, Vol. 22 Issue 10, p35
Focuses on the growth of prescription drug benefit plans for workers. Percentage of workers with health insurance; Control of prescription drug cost; Cost of pharmaceuticals in the three-tiered plans.
- NCPDP to use its award to boost standard Rx cards. Ukens, Carol // Drug Topics;4/17/2000, Vol. 144 Issue 8, p121
Unveils the plan of the National Council for Prescription Drug Programs (NCPDP) to use a grant to promote its implementation guide for the standard drug benefit card format. Amount of the grant; Purpose of the cash infusion; Information on drug card format.
- Value 'more important' than cost in drug coverage decisions. Fleming Jr., Harris // Drug Topics;4/17/2000, Vol. 144 Issue 8, p97
Discusses the importance of value, rather than cost, in drug coverage decisions in the United States. Details on the study conducted by the Clinical Bioethics Department at the National Institute of Health's Clinical Center and the Agency for Health Research & Quality; Information on the...
- Industry scrambles to brake healthcare's fastest-growing cost. Wechsler, Jill // Managed Healthcare Executive;May2002, Vol. 12 Issue 5, p9
Focuses on the increase of prescription drugs at double-digit rates in 2001 in the U.S. Study conducted from the National Institute of Health Care Management; Statistics on the retail spending on prescription drugs; Plans on the establishment of Congress of Medicare drug benefit.
- To win generic discounts, third-party contracts crucial. Breau, Joseph // Drug Topics;11/20/95 Generics, Vol. 139 Issue 22, p18S
Reports on the effective efforts of pharmacy purchasing groups and pharmacy service administrative organizations in getting discounts and rebates from generic drug companies. Estimated volume of generic drugs used; Ability of the organizations to adapt to the industry; Forecasts on growth of...
- New drugs, more demand, raising drug benefit costs. Roberts, Sally // Business Insurance;12/14/98, Vol. 32 Issue 50, p3
Asserts that the increase in prescription benefit costs in the United States is influenced by the demand for new drugs for various ailments. Increase in number of new drugs approved by the Food and Drug Administration in 1997; Advertising campaigns from drug manufacturers to increase consumer...